Search - tctmd.com

Displaying 1 - 20 of 217

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Yael L. Maxwell

January 21, 2026

News Daily News

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Michael O'Riordan

January 09, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

Yael L. Maxwell

May 05, 2025

News Daily News

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Michael O'Riordan

May 02, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

Previewing 30-Year ASCVD Risk May Open Door to Earlier Treatment

Lp(a) Linked to 30-Year CVD Risk in Healthy Women

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Year in Review: Top Prevention Stories of 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Lp(a) Genetics Differ Between Populations but Have Similar Clinical Impact

HDL Cholesterol Levels May Sway Statin Decisions in Primary Prevention

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content